New eye disease drug trial uses High-Tech scans to track progress
NCT ID NCT07423013
Summary
This study is testing a medication called Teprotumumab N01 for people with active Thyroid Eye Disease (TED), a condition that causes eye bulging, double vision, and swelling. Fifty participants will receive the drug and have their eye symptoms and quality of life tracked for 24 weeks. Doctors will use special PET/CT and MRI scans to see detailed changes in the eye tissues and measure how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.